It remains to be explored whether in DUX4-positive ALL, the IKZF1plus signature maintains its association with a poor prognosis, and, if this is not the case, whether unnecessary treatment intensification can be avoided. This evidence concerns the gene DUX4 and acute lymphoblastic leukemia.